Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis

• Published in: Annals of the rheumatic diseases Vol. 72; no. 6; pp. 1003 - 1010
• Main Authors: Mahr, Alfred, Katsahian, Sandrine, Varet, Hugo, Guillevin, Loïc, Hagen, E Christiaan, Höglund, Peter, Merkel, Peter A, Pagnoux, Christian, Rasmussen, Niels, Westman, Kerstin, Jayne, David R W
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2013; Elsevier Limited
• Subjects: Adeno-associated virus; Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - classification; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - physiopathology; Antibodies, Antineutrophil Cytoplasmic - immunology; Classification; Clinical Medicine; Clinical trials; Cluster Analysis; Disease; Female; Granulomatosis with Polyangiitis - classification; Granulomatosis with Polyangiitis - immunology; Granulomatosis with Polyangiitis - physiopathology; Humans; Immunoglobulins; Klinisk medicin; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Microscopic Polyangiitis - classification; Microscopic Polyangiitis - immunology; Microscopic Polyangiitis - physiopathology; Middle Aged; Neutrophils; Randomized Controlled Trials as Topic; Studies
• ISSN: 0003-4967; 1468-2060; 1468-2060
• DOI: 10.1136/annrheumdis-2012-201750

Background Granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA) are subgroups of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) defined historically by clinical and histological features. GPA and MPA are heterogeneous entities with overlapping phenotypes. To identify novel subgroupings, cluster analysis was used to explore the phenotypic spectrum of AAV. Methods This study used a dataset of patients newly diagnosed as having GPA and MPA enrolled in five clinical trials. One cluster model included nine clinical baseline variables as input variables, and a second cluster model additionally included ANCA specificities. The clustering process involved multiple correspondence analyses followed by hierarchical ascendant cluster analysis. The clinical relevance of the generated clusters was analysed by their summary characteristics and outcomes. Results The analyses involved data for 673 subjects: 396 (59%) with GPA and 277 (41%) with MPA. Both cluster models resulted in five partially redundant clusters of subjects, and the model including ANCA resulted in more pertinent separations. These clusters were named ‘renal AAV with proteinase 3 (PR3)-ANCA’ (40% of subjects), ‘renal AAV without PR3-ANCA’ (32%) and ‘non-renal AAV’ (12%), ‘cardiovascular AAV’ (9%) and ‘gastrointestinal AAV’ (7%). The five clusters had distinct death and relapse rates. On the basis of 4 variables, 651 subjects (97%) could be accurately allocated to 1 of the 5 classes. Conclusions This analysis suggests that AAV encompasses five classes associated with different outcomes. As compared with the traditional GPA–MPA separation, this classification system may better reflect the phenotypic spectrum of AAV.